This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Immuneering Corporation Expands Alliance With Bristol-Myers Squibb

CAMBRIDGE, Mass., Jan. 29, 2014 /PRNewswire/ -- Immuneering Corporation announced today that it has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (NYSE: BMY) for the use of Immuneering's proprietary computational biology methods to identify biological insights that may facilitate discovery and development of medicines. Terms of agreement were not disclosed.

(Logo: http://photos.prnewswire.com/prnh/20140129/NE54258LOGO )

"It is a pleasure to expand our collaboration with Bristol-Myers Squibb, said Dr. Ben Zeskind, Immuneering's CEO.  "Medicines that unleash the immune system against cancer have a demonstrated ability to produce, in certain cases, the durable complete responses that cancer patients so urgently need.  We are pleased to help elucidate the mechanisms driving these responses."

Immuneering's team of MIT-trained PhDs will perform advanced analyses on data from Bristol-Myers Squibb to derive new biological insights.  Immuneering uses internally developed proprietary algorithms in combination with software licensed from leading research institutions.

Immuneering's proprietary algorithms extend beyond traditional analysis methods, capturing difficult-to-find signals by analyzing data in ways uniquely aligned with the underlying biological mechanisms.  This enables Immuneering to uncover novel biological information from complex data sets.

About Immuneering Corporation

Immuneering Corporation ( http://www.immuneering.com) helps leading pharmaceutical companies use genetic, genomic, and proteomic data to generate biological insights that enhance the clinical and commercial success of medicines.  Immuneering's team of MIT-trained PhDs provides advanced data analysis services using state of the art technologies including proprietary algorithms.  Headquartered in Cambridge, MA, Immuneering is a profitable and growing company with nearly 6 years of experience analyzing data sets ranging from gene expression (microarray) data, to single-nucleotide polymorphism (SNP) data, to protein concentration data, to clinical meta data, to next-generation sequencing (NGS) data including RNAseq, exome sequencing, and whole genome sequencing.  Using these data sets, Immuneering captures difficult-to-find signals, generates biological hypotheses, and designs follow up studies, contributing to the development of medicines for patients with cancer, autoimmune disease, neurodegeneration, and other serious diseases.

CONTACT: Dr. Ben Zeskind, CEO, bzeskind@immuneering.com, 617-500-8080 ext. 121.

Web site: http://www.immuneering.com

SOURCE Immuneering Corporation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs